Compared to controls, mice treated with GRI-0621 showed histological improvement in fibrotic lesion in the lung; Inhibition of iNKT activity led to a decrease in fibrosis score and total lung inflammation LA JOLLA, CA, July 02, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the publication o ...

Compared to controls, mice treated with GRI-0621 showed histological improvement in fibrotic lesion in the lung; Inhibition of iNKT activity led to a decrease in fibrosis score and total lung inflammation LA JOLLA, CA, July 02, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the publication o ...

LA JOLLA, CA, July 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Vipin Kumar Chaturvedi, PhD, Chief Scientific Officer of GRI Bio, will present at the 8th Annual IPF Summit taking place August 20-22, 2024 in Boston, MA. About GRI Bio, Inc. | --- | |-------------------| | | | Inves ...

The gross proceeds to the Company from the offering, before deducting the placement agent's fees and other offering expenses payable by the Company, were approximately $4.0 million. The potential additional gross proceeds to the Company from the Series Warrants, if fully exercised on a cash basis, will be approximately $8.0 million. No assurance can be given that any of the Series Warrants will be exercised for cash. The Company intends to use the net proceeds from this offering for its product candidate de ...

LA JOLLA, CA, June 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the closing of its previously announced public offering for the purchase and sale of an aggregate of 2,185,793 shares of its common stock (or common stock equivalents in lieu thereof), Series C-1 warrants to purchase up ...

LA JOLLA, CA, June 27, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the Korean Intellectual Property Office (KIPO) has granted Patent No. 10-2665487 titled, "Prevention and Treatment of Inflammatory Conditions." GRI Bio is currently advancing its lead program GRI-0621, a small molecul ...

GRI Bio (NASDAQ:GRI) stock is falling on Wednesday after the clinical-stage biopharmaceutical company announced a proposed public offering for its shares. GRI Bio plans to offer up to 2,238,806 shares of GRI stock. Each of these shares comes with one Series C-1 warrant and one Series C-2 warrant. Each of these can be exercised for another share of GRI. GRI Bio doesn't have a firm price ready for its public offering just yet. Instead, it's operating off of an assumed price of $2.68 per share. This is also th ...

GRI's common stock is expected to begin trading on a post-split adjusted basis on June 18, 2024 The 1-for-13 Reverse Split will automatically convert every thirteen (13) current shares of the Company's common stock into one (1) share of common stock. No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise hold a fractional share of the Company's common stock following the reverse stock split will receive a cash payment in lieu thereof at a price equal ...

Company Overview - GRI Bio, Inc. is a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for treating inflammatory, fibrotic, and autoimmune diseases [3][9] - The company's lead program, GRI-0621, is an oral therapeutic aimed at treating idiopathic pulmonary fibrosis, addressing a significant unmet medical need [9] - GRI Bio is also developing a pipeline of novel type 2 NKT agonists for systemic lupus erythematosus and has a library of over 500 proprietary compounds to support its pipeline [9] Reverse Stock Split Announcement - The board of directors approved a 1-for-13 reverse stock split, reducing the number of outstanding shares from approximately 6,605,271 to about 508,091 shares [3][8] - The reverse split is intended to increase the per share trading price to comply with Nasdaq's minimum bid price requirement [3][6] - The reverse split will take effect on June 17, 2024, and trading under a new CUSIP number will begin on June 18, 2024 [3][6] Stockholder Impact - Stockholders holding shares electronically will not need to take action to receive post-split shares, while those with physical certificates will receive instructions for exchanging them [6][8] - No fractional shares will be issued; stockholders entitled to a fractional share will receive a cash payment based on the adjusted closing sale price [8]

LA JOLLA, CA, June 11, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio," "we," "our," or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced it will present at the Virtual Investor Pitch Conference on June 18, 2024 at 11:00 AM ET. About GRI Bio, Inc. Live video webcast on Tuesday, June 18th at 11:00 AM ET A live video webcast of the presentation wi ...